Verana Health Launches Neurology Qdata
Verana Health today announced the launch of its Neurology Qdata, available through Verana Health's real-world evidence service offerings.
Neurology Qdata comprises disease-specific datasets to help power neuroscience research and shape therapeutic strategies. Qdata SMA, the first neurology module to launch, is a real-world de-identified dataset reflective of spinal muscular atrophy (SMA) patients found across healthcare settings.
Following the release of Qdata SMA, Verana Health expects to release additional Neurology Qdata modules for neurological diseases including Parkinson's Disease, multiple sclerosis, Neuromyelitis Optica Spectrum Disorder (NMOSD), and others.
Read more about this new model here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
